1. Fontan F, Choussat A, Deville C, Doutremepuich C, Coupillaud J, Vosa C. Aortic valve homografts in the surgical treatment of complex cardiac malformations. J Thorac Cardiovasc Surg, vol. 87, pp. 649-57, 1984.
2. Ross D. Pulmonary valve autotransplantation (the Ross operation). J Card Surg, vol. 3, pp. 313-9, 1988.
3. Motomura N, Takamoto S, Murakawa T, Yoneda N, Shibusawa S, Maeda K, Suematsu Y, Murakami A, Nakajima J, and Kotsuka Y. Short-term result of aortic valve replacement with cryopreserved homograft valve in the University of Tokyo Tissue Bank. Artif Organs, vol. 26, pp. 449–52, 2002.
4. Burkhart HM, Ashburn DA, Konstantinov IE, and De Oliviera NC. Interdigitating arch reconstruction eliminates recurrent coarctation after the Norwood Procedure. J Thorac Cardiovasc Surg, vol. 130, pp. 61-5, 2005.
5. Klieverik LM, Bekkers JA, Roos JW, Eijkemans MJ, Raap GB, Bogers AJ, and Takkenberg JJ. Autograft or allograft aortic valve replacement in young adult patients with congenital aortic valve disease. European Heart Journal, vol. 29, pp. 1446–53, 2008.
6. O'Brien MF, Harrocks S, Stafford EG, Gardner MA, Pohlner PG, Tesar PJ, Stephens F. The homograft aortic valve: a 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis. vol. 10, pp. 334-44, 2001.
7. Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD, Fedderly RT, Berger S, Frommelt MA, Lewis DA, Friedberg DZ, Thomas JP Jr, Sachdeva R, Litwin SB. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circulation, vol. 102, pp. 130-5, 2000.
8. Doty JR, Salazar JD, Liddicoat JR, Flores JH, Doty DB. Aortic valve replacement with cryopreserved aortic allograft: ten-year experience. J Thorac Cardiovasc Surg, vol. 115, pp. 371-80, 1998.
9. O'Brien MF, Stafford EG, Gardner MA, Pohlner PG, Tesar PJ, Cochrane AD, Mau TK, Gall KL, Smith SE. Allograft aortic valve replacement: long-term follow-up. Ann Thorac Surg, vol. 60, pp. 65-70, 1995.
10. Arabkhani B, Bekkers JA, Andrinopoulou ER, Roos-Hesselink JW, Takkenberg JJ, Bogers AJ. Allografts in aortic position: Insights from a 27-year, single-center prospective study. J Thorac Cardiovasc Surg, vol. 152, pp. 1572-1579, 2016.
11. Yankah AC, Alexi-Meskhishvili V, Weng Y, Schorn K, Lange PE, Hetzer R. Accelerated degeneration of allografts in the first two years of life. Ann Thorac Surg, vol. 60, pp. 71-76, 1995.
12. Musci M, Weng Y, Hübler M, Amiri A, Pasic M, Kosky S, Stein J, Siniawski H, Hetzer R. Homograft aortic root replacement in native or prosthetic active infective endocarditis: twenty-year single-center experience. J Thorac Cardiovasc Surg, vol. 139, pp. 665-73, 2010.
13. Eguchi S, Asano K. Homograft of pulmonary artery or ascending aorta with valve as a right ventricular outflow. J Thorac Cardiovasc Surg, vol. 56, pp. 413-20, 1968.
14. Daly RC, Orszulak TA, Schaff HV, McGovern E, Wallace RB. Long-term results of aortic valve replacement with nonviable homografts. Circulation, vol. 84, pp. 81-8, 1991.
15. di Carlo D, de Leval MR, Stark J. "Fresh", antibiotic sterilized aortic homografts in extracardiac valved conduits. Long-term results. Thorac Cardiovasc Surg, vol. 32, pp. 10-4, 1984.
16. Barratt-Boyes BG, Roche AH, Subramanyan R, Pemberton JR, Whitlock RM. Long-term follow-up of patients with the antibiotic-sterilized aortic homograft valve inserted freehand in the aortic position. Circulation, vol. 75, 768-77, 1987.
17. O'Brien MF, Stafford EG, Gardner MA, Pohlner PG, McGiffin DC. A comparison of aortic valve replacement with viable cryopreserved and fresh allograft valves, with a note on chromosomal studies. J Thorac Cardiovasc Surg, vol. 94, pp. 812-23, 1987.
18. O'Brien MF, Stafford G, Gardner M, Pohlner P, McGiffin D, Johnston N, Brosnan A, Duffy P. The viable cryopreserved allograft aortic valve. J Card Surg, vol. 2, pp. 153-67, 1987.
19. Mirabet V, Carda C, Solves P, Novella-Maestre E, Carbonell-Uberos F, Caffarena JM, Hornero F, Montero JA, Roig RJ. Long-term storage in liquid nitrogen does not affect cell viability in cardiac valve allografts. Cryobiology, vol. 57, pp. 113-21, 2008.
20. Mitchell RN, Jonas RA, Schoen FJ. Structure-function correlations in cryopreserved allograft cardiac valves. Ann Thorac Surg, vol. 60, pp. 108-12, 1995.
21. Baskett RJ, Ross DB, Nanton MA, Murphy DA. Factors in the early failure of cryopreserved homograft pulmonary valves in children: preserved immunogenicity? J Thorac Cardiovasc Surg, vol. 112, pp. 1170-8, 1996.
22. Smith JD, Ogino H, Hunt D, Laylor RM, Rose ML, Yacoub MH. Humoral immune response to human aortic valve homografts. Ann Thorac Surg, vol. 60, pp. 127-30, 1995.
23. den Hamer I, Hepkema B, Prop J, Elzenga N, Ebels T. HLA antibodies specific for cryopreserved heart valve "homografts" in children. J Thorac Cardiovasc Surg, vol. 113, pp. 417-9, 1997.
24. Rajani B, Mee RB, Ratliff NB. Evidence for rejection of homograft cardiac valves in infants. J Thorac Cardiovasc Surg, vol. 115, pp. 111-7, 1998.
25. Vogt PR, Stallmach T, Niederhäuser U, Schneider J, Zünd G, Lachat M, Künzli A, Turina MI. Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Eur J Cardiothorac Surg, vol. 15, pp. 639-44, 1999.
26. Shaddy RE, Hunter DD, Osborn KA, Lambert LM, Minich LL, Hawkins JA, McGough EC, Fuller TC. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation, vol. 94, pp. 1063-7, 1996.
27. Shaddy RE, Hawkins JA. Immunology and failure of valved allografts in children. Ann Thorac Surg, vol. 74, pp. 1271-5, 2002.
28. Neidert MR, Tranquillo RT. Tissue-engineered valves with commissural alignment. Tissue Eng, vol. 12, pp. 891-903, 2006.
29. Gerson CJ, Elkins RC, Goldstein S, Heacox AE. Structural integrity of collagen and elastin in SynerGraft® decellularized-cryopreserved human heart valves. Cryobiology, vol. 64, pp. 33-42, 2012.
30. Elkins RC, Dawson PE, Goldstein S, Walsh SP, Black KS. Decellularized human valve allografts. Ann Thorac Surg, vol. 71, pp. 428-32, 2001.
31. Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U, Rieder E, Wolner E. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg, vol. 23, pp. 1002-6, 2003.
32. Perri G, Polito A, Esposito C, Albanese SB, Francalanci P, Pongiglione G, Carotti A. Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outflow tract reconstruction in patients with congenital heart disease. Eur J Cardiothorac Surg, vol. 41, pp. 1320-5, 2012.
33. Brown JW, Ruzmetov M, Eltayeb O, Rodefeld MD, Turrentine MW. Performance of SynerGraft decellularized pulmonary homograft in patients undergoing a Ross procedure. Ann Thorac Surg, vol. 91, pp. 416-22, 2011.
34. Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg, vol. 7, pp. 82-92, 1988.
35. Räisänen-Sokolowski A, Vuoristo P, Myllärniemi M, Yilmaz S, Kallio E, Häyry P. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol, vol. 3, pp. 342-51, 1995.
36. Chang Q, Jing H, Sun M, Xu P. Exploring the role of short-course cyclosporin a therapy in preventing homograft valve calcification after transplantation. Cell Immunol, vol. 287, pp. 36-45, 2014.
37. Shaddy RE, Lambert LM, Fuller TC, Profaizer T, Thompson DD, Baker SI, Osborne KA, Hawkins JA. Prospective randomized trial of azathioprine in cryopreserved valved allografts in children. Ann Thorac Surg, vol. 71, pp. 43-7, 2001.
38. Mitchell RN, Jonas RA, Schoen FJ. Pathology of explanted cryopreserved allograft heart valves: comparison with aortic valves from orthotopic heart transplants. J Thorac Cardiovasc Surg, vol. 115, pp. 118-27, 1998.
39. Woda CB, Halaihel N, Wilson PV, Haramati A, Levi M, Mulroney SE. Regulation of renal NaPi-2 expression and tubular phosphate reabsorption by growth hormone in the juvenile rat. Am J Physiol Renal Physiol, vol. 287, pp. 117-23, 2004.
40. Yamauchi H, Motomura N, Chung UI, Sata M, Takai D, Saito A, Ono M, Takamoto S. Growth-associated hyperphosphatemia in young recipients accelerates aortic allograft calcification in a rat model. J Thorac Cardiovasc Surg, vol. 145, pp. 522-30, 2013.
41. Kinoshita O, Yamauchi H, Motomura N, Ono M. Lanthanum carbonate, a phosphate binder, inhibits calcification of implanted aortic allografts in a rat model. Gen Thorac Cardiovasc Surg, 2018. [Epub ahead of print]
42. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, vol. 342, pp. 1478-83, 2000.
43. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. vol. 31, pp. 607-17, 1998.
44. 北村正樹. 高リン血症治療薬 リン吸着薬. 耳鼻咽喉科展望, vol. 58, pp. 312-314, 2015.
45. M. Zalman S Agus. Signs and symptoms of hypophosphatemia. UpToDate, pp. 13–15, 2012.
46. Kenichi Okamura, Haruo Yamauchi, Osamu Kinoshita, and Minoru Ono. Short-term lanthanum carbonate safely inhibits aortic allograft calcification and intimal hyperplasia in a rabbit circulatory transplant model. Circulation, vol. 136, A13739, 2018. https://www.ahajournals.org/doi/abs/10.1161/circ.136.suppl_1.13739
47. Shimokawa S, Matsumoto H, Ogata S, Komokata T, Nishida S, Ushijima T, Saigenji H, Moriyama Y, Taira A. A new experimental model for simultaneous evaluation of aortic and pulmonary allograft performance in a composite graft. J Invest Surg, vol. 9, pp. 487-93, 1996.
48. 日本フリーザー株式会社. プログラムフリーザーTNP-87S 型取り扱い説明書. pp. 12-15.
49. Minatoya K, Seike Y, Itonaga T, Oda T, Inoue Y, Kawamoto N, Miura S, Tanaka H, Sasaki H, Kobayashi J. Straight incision for extended descending and thoracoabdominal aortic replacement: novel and simple exposure with rib-cross thoracotomy. Interact Cardiovasc Thorac Surg, vol. 23, pp. 367-70, 2016.
50. Morgan SL, Prater GL. Quality in dual-energy X-ray absorptiometry scans. Bone, vol. 104, pp. 13-28, 2017.
51. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone, vol. 14, pp. 595-608, 1993.
52. Jämsä T, Jalovaara P, Peng Z, Väänänen HK, Tuukkanen J. Comparison of three-point bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia. Bone, vol. 23, pp. 155-61, 1998.
53. Leppänen O, Sievänen H, Jokihaara J, Pajamäki I, Järvinen TL. Three-point bending of rat femur in the mediolateral direction: introduction and validation of a novel biomechanical testing protocol. J Bone Miner Res, vol. 21, pp. 1231-7, 2006.
54. Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J, vol. 156, pp. 556-63, 2008.
55. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res, vol. 109, pp. 697-711, 2011.
56. Querfeld U. The clinical significance of vascular calcification in young patients with end-stage renal disease. Pediatr Nephrol, vol. 19, pp. 478-84, 2004.
57. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res, vol. 87, pp. 10-7, 2000.
58. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation, vol. 117, pp. 2938-48, 2008.
59. Lanzer P, Boehm M, Sorribas V, Thiriet M, Janzen J, Zeller T, St Hilaire C, Shanahan C. Medial vascular calcification revisited: review and perspectives. Eur Heart J, vol. 35, pp. 1515-25, 2014.
60. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int, vol. 75, pp. 890-7, 2009.
61. Cola C, Almeida M, Li D, Romeo F, Mehta JL. Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun, vol. 320, pp. 424-7, 2004.
62. Csiszar A, Smith KE, Koller A, Kaley G, Edwards JG, Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation, vol. 111, pp. 2364-72, 2005.
63. Tintut Y, Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Investig Med, vol. 54, pp. 395-401, 2006.
64. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol, vol. 27, pp. 2589-96, 2007.
65. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol, vol. 65, pp. 297-302, 1990.
66. Fukumoto Y, Shimokawa H, Ito A, Kadokami T, Yonemitsu Y, Aikawa M, Owada MK, Egashira K, Sueishi K, Nagai R, Yazaki Y, Takeshita A. Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. J Cardiovasc Pharmacol, vol. 29, pp. 222-31, 1997.
67. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation, vol. 100, pp. 2168-76, 1999.
68. Brockbank KG, Lightfoot FG, Song YC, Taylor MJ. Interstitial ice formation in cryopreserved homografts: a possible cause of tissue deterioration and calcification in vivo. J Heart Valve Dis, vol. 9, pp. 200-6, 2000.
69. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg, vol. 79, pp. 1072-80, 2005.
70. Schenke-Layland K, Madershahian N, Riemann I, Starcher B, Halbhuber KJ, König K, Stock UA. Impact of cryopreservation on extracellular matrix structures of heart valve leaflets. Ann Thorac Surg, vol. 81, pp. 918-26, 2006.
71. Rucker RB. Calcium binding to elastin. Adv Exp Med Biol, vol. 48, pp. 185-209, 1974.
72. Schneider M, Stamm C, Brockbank KGM, Stock UA, Seifert M. The choice of cryopreservation method affects immune compatibility of human cardiovascular matrices. Sci Rep, vol. 7, pp. 1702-7, 2017.
73. Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, Senda Y, Maemura K, Nakano T, Akishita M, Ouchi Y. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res, vol. 98, pp. 1024-31, 2006.
74. Jian B, Narula N, Li QY, Mohler ER 3rd, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg, vol. 75, pp. 457-65, 2003.
75. Schober A, Hoffmann R, Oprée N, Knarren S, Iofina E, Hutschenreuter G, Hanrath P, Weber C. Peripheral CD34+ cells and the risk of in-stent restenosis in patients with coronary heart disease. Am J Cardiol, vol. 96, pp. 1116-22, 2005.
76. Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, Shimizu M, Komoda H, Node K. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation, vol. 115, pp. 553-61, 2007.
77. Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res, vol. 114, pp. 590-600, 2018.
78. Thubrikar MJ, Deck JD, Aouad J, Nolan SP. Role of mechanical stress in calcification of aortic bioprosthetic valves. J Thorac Cardiovasc Surg, vol. 86, pp. 115-25, 1983.
79. Cornhill JF, Barrett WA, Herderick EE, Mahley RW, Fry DL. Topographic study of sudanophilic lesions in cholesterol-fed minipigs by image analysis. Arteriosclerosis, vol. 5, pp. 415-26, 1985.
80. Branchetti E, Poggio P, Sainger R, Shang E, Grau JB, Jackson BM, Lai EK, Parmacek MS, Gorman RC, Gorman JH, Bavaria JE, Ferrari G. Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. Cardiovasc Res, vol. 100, pp. 316-24, 2013.
81. Cleveland DC, Williams WG, Razzouk AJ, Trusler GA, Rebeyka IM, Duffy L, Kan Z, Coles JG, Freedom RM. Failure of cryopreserved homograft valved conduits in the pulmonary circulation. Circulation, vol. 86, pp. 150-3, 1992.
82. Clarke DR, Bishop DA. Allograft degeneration in infant pulmonary valve allograft recipients. Eur J Cardiothorac Surg, vol. 7, pp. 365-70, 1993.
83. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation, vol. 107, pp. 2181-4, 2003.
84. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation, vol. 111, pp. 3316-26, 2005.
85. Leopold JA. Cellular mechanisms of aortic valve calcification. Circ Cardiovasc Interv, vol. 5, pp. 605-14, 2012.